Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of L-DOPA treatment

Karen L. Eskow Jaunarajs\textsuperscript{a}, Mariana Angoa-Perez\textsuperscript{b}, Donald M. Kuhn\textsuperscript{b}, and Christopher Bishop\textsuperscript{a}

\textsuperscript{a}Behavioral Neuroscience Program, Department of Psychology, State University of New York at Binghamton, Binghamton, NY, USA

\textsuperscript{b}Department of Psychiatry & Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA

Abstract

Though the most recognizable symptoms of Parkinson's disease (PD) are motor-related, many patients also suffer from debilitating affective symptoms that deleteriously influence quality of life. Dopamine (DA) loss is likely involved in the onset of depression and anxiety in PD. However, these symptoms are not reliably improved by DA replacement therapy with L-3,4-dihydroxyphenylalanine (L-DOPA). In fact, preclinical and clinical evidence suggests that L-DOPA treatment may worsen affect. Though the neurobiological mechanisms remain unclear, recent research contends that L-DOPA further perturbs the function of the norepinephrine and serotonin systems, already affected by PD pathology, which have been intimately linked to the development and expression of anxiety and depression. As such, this review provides an overview of the clinical characteristics of affective disorders in PD, examines the utility of animal models for the study of anxiety and depression in PD, and finally, discusses potential mechanisms by which DA loss and subsequent L-DOPA therapy influence monoamine function and concomitant affective symptoms.

Keywords

Parkinson's disease; L-DOPA; anxiety; depression; affect; animal models; serotonin; dopamine; norepinephrine

1. Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects dopamine (DA) neurons of the substantia nigra pars compacta (SNc). The loss of DA from nigral projections leads to difficulty with movement, including slowness or lack of movement, rigidity, postural instability, and resting tremor. Though less acknowledged, PD patients also suffer from a variety of non-motor symptoms, including significant changes in
affect that deleteriously impact their quality of life (Carod-Artal et al., 2008; McKinlay et al., 2008; Schrag, 2006). L-3,4-dihydroxyphenylalanine (L-DOPA) has been the gold standard for PD pharmacotherapy and the majority of patients will receive it at some point during their treatment. However, there may be an association between DA replacement therapy and psychological symptoms that extend beyond disease state and DA cell loss. In support, affective disorders may manifest prior to the onset of motor symptoms (Aarsland et al., 2009; Nilsson et al., 2001; Schuurman et al., 2002), neither anxiety nor depression is reliably improved by L-DOPA treatment (Kim et al., 2009; Nègre-Pagès et al., 2010), and L-DOPA may exacerbate affective symptoms in later stages of PD when its efficacy is compromised (Richard et al., 2004).

The NE and 5-HT systems are also substantially affected by the PD process in most patients (Frisina et al., 2009; Kish et al., 2008) and may be implicated in primary affective symptoms or those that result from L-DOPA treatment. For example, recent studies in animal models of PD suggest that L-DOPA may interfere with NE and 5-HT function in affect-related brain structures and induce symptoms of anxiety and depression (Eskow Jaunarajs et al., in press; Navailles et al., 2010a, 2010b). As such, this review provides an overview of the clinical characteristics of anxiety and depression in PD, examines the utility of animal models for the study of affective disorders in PD, and finally, discusses potential mechanisms by which DA loss and subsequent L-DOPA therapy influence monoamine function and concomitant affective symptoms.

2. Affective disorders in PD

Reported prevalences of affective disorders in PD are disparate, with studies reporting rates anywhere from 2% (Hantz et al., 1994) to 76% (Happe et al., 2001) for depression and 5% (Lauterbach & Duvoisin, 1991) to 69% (Kulisevsky et al., 2008) for anxiety. Nuti and colleagues (2004) observed that ~30% of patients suffering from depression in PD also experienced panic disorder and an additional 11% expressed generalized anxiety, compared to 5.5% of control populations. As notable, depression is the single most important factor in PD patients' reported quality of life, above disease severity and motor complications of L-DOPA therapy (Schrag, 2006). Furthermore, while anxiety is perhaps one of the least studied psychiatric complications diagnosed in PD patients, it is also associated with reduced quality of life (McKinlay et al., 2007).

2.1. Depression

Depressive symptoms overlap with PD symptoms and are often assumed to be synonymous with motor impairment: psychomotor retardation, attention deficit, day-night sleep reversal, weight loss, fatigue, and reduced facial expression (often called facial “masking”). In contrast to major depressive disorder, suicidal tendencies or expressions of guilt and self-blame are rarely observed in PD patients (Brooks & Doder, 2001; Lemke, 2008; Starkstein et al., 2008). Depression in PD is commonly treatment refractory, although it is possible that PD patients receive insufficient dosage of antidepressants in order to ensure that drug interactions to not worsen parkinsonism (Weintraub et al., 2003). As with anxiety symptoms, primary care physicians and caregivers either do not recognize affective symptoms or assume that PD with depression is merely a psychological side effect of chronic disease state. However, comorbidity of depression in PD (~1 in 2) exceeds that found in the general population (1 in 50; Beekman et al., 1999) or in other chronic and/or neurodegenerative diseases, such as multiple sclerosis (Chwastiak et al., 2002), Alzheimer’s disease (Wragg & Jeste, 1989), and rheumatoid arthritis (Cantello et al., 1986). Furthermore, affective symptoms in PD are not influenced by the severity of motor symptoms. Multiple groups have confirmed that neither depression nor anxiety are correlated with motor disability (Huber et al., 1988; Mondolo et al., 2007; Nègre-Pagès et al., 2010; Santangelo et
In fact, patients often report depression and anxiety even when their motor status is improved by pharmacotherapy or neurosurgery (Kostic et al., 1987; Marsh & Markham, 1973; Wang et al., 2009). Depression is frequently the presenting symptom before significant motor symptoms are observed, and therefore, may be considered a risk factor for PD (Aarsland et al., 2009; Nilsson et al., 2001; Schuurman et al., 2002; Tandberg et al., 1996; Ziemssen & Reichmann, 2007). As such, depression is more likely a consequence of the disease process, and not simply the result of psychological distress due to the development of a chronic disease.

2.2. Anxiety

A number of subtypes of anxiety are observed in the PD patient population, especially panic disorder, simple and social phobias, and generalized anxiety (Lauterbach et al., 2004; Pontone et al., 2009). In a recent study by Mondolo and colleagues (2007), PD patients with anxiety equated their symptoms to an inability to relax, restlessness, and feeling tense. Most investigations suggest that anxiety is more prevalent in the OFF phase of L-DOPA treatment, when the patient is lacking the beneficial effects of treatment on motor symptoms of PD (Racette et al., 2002; Stein et al., 1990; Siemers et al., 1993) and is traditionally correlated with stress due to the onset of parkinsonism. However, anxiety rates in PD populations exceed those in normal and chronic disease affected populations (Richard et al., 1996) and has been posited as a risk factor for PD, since it, like depression, may manifest before the onset of motor symptoms (Shiba et al., 2000). In fact, more severe anxiety was highly associated with onset of PD after a 12-year follow-up in patients originally suffering from simple phobias (Weisskopf et al., 2003). Such findings suggest that anxiety is not simply a factor of motor impairment alone, but reflects a neuropathological, disease-related susceptibility.

3. Effects of L-DOPA treatment on affective disorders in PD

Traditionally, L-DOPA has been reported to improve affect (Yahr et al., 1969). However, as shown in Table 1, contemporary research has been conflicting. Indeed, the only investigations in de novo PD patients have revealed that L-DOPA either does not influence (Kim et al., 2009; Marsh & Markham, 1973) or exacerbates (Choi et al., 2000; Damasio et al., 1971) depression, while even less is known of the effects of L-DOPA on anxiety.

3.1. Depression

Historically, L-DOPA treatment has been attributed to a profound recovery in mood in PD patients (Yahr et al., 1969). However, few studies have been conducted in order to confirm the effects of L-DOPA treatment on depression. Of these, slight improvements in mood have been shown in some instances (Funkiewicz et al., 2006; Growdon et al., 1998). For example, acute L-DOPA treatment was shown to reduce scores on the Beck Depression Inventory (BDI) and apathy in a small group of PD patients (Witt et al., 2006). However, other studies have not confirmed the antidepressant effects of L-DOPA. In a classic study by Marsh and Markham (1973), depression was not improved even after 15 months of L-DOPA treatment in 27 de novo PD patients. A more recent study in initially de novo PD patients revealed that 3 months of L-DOPA treatment did not significantly alter mood (Kim et al., 2009). Furthermore, Choi and colleagues (2000) treated 34 de novo patients with L-DOPA for 6 and 28 months. They observed that 11 patients suffered from depression prior to L-DOPA treatment, while 14 were clinically depressed following L-DOPA treatment. In corroboration, depression was correlated with receiving L-DOPA therapy in a sample of over 400 PD patients (Nègre-Pagès et al., 2010) and depressed PD patients consistently receive higher doses of L-DOPA (Palhagen et al., 2008; Suzuki et al., 2008; Weintraub et al., 2006; but see Starkstein et al., 1990).
3.2. Anxiety

While some groups have reported significant improvements in anxiety upon L-DOPA treatment (Funkiewicz et al., 2003; Maricle et al., 1995; Stacy et al., 2010), others have asserted that there is no such improvement or that L-DOPA exacerbates anxiety (Damasio et al., 1971; Richard et al., 1996; Vazquez et al., 1993). Such disparate findings may be due to the cyclic pharmacokinetic nature of chronic L-DOPA treatment, consisting of several ON/OFF phases within a 24 h period. Subtypes of anxiety due to a specific motor deficit (i.e. fear of falling, agoraphobia) are substantially reduced upon onset of motor improvement due to L-DOPA treatment during the ON phase (Maricle et al., 1995; Pontone et al., 2009). Though panic attacks are usually observed in the OFF phase, they can manifest during the ON phase along with agitation and mania (Damasio et al., 1971; Pontone et al., 2009; Vazquez et al., 1993). Thus, it appears that chronic L-DOPA treatment may have enduring effects on anxiety disorders in PD. In support, Vazquez and colleagues (1993) observed that PD patients who experienced regular panic attacks were on a higher dose of L-DOPA and were more likely to experience dyskinesias and motor fluctuations than non-anxious PD patients. Though the collective data suggests that L-DOPA may be associated with exacerbation of anxiety, no placebo-controlled studies have been conducted in de novo PD patients in order to adequately determine its effects.

Collectively, these findings suggest that the effects of chronic L-DOPA on affective symptoms of PD are limited and that pharmacotherapy may even aggravate them. However, no blinded, placebo-controlled studies on the effects of DA replacement therapy on anxiety and depression have been completed in de novo patients to date. This is likely due to ethical constraints and highlights the need for preclinical models of the affective symptoms in PD.

4. Animal models of depression and anxiety symptoms in PD

There are several neurotoxin-related animal models of PD which mimic the nigrostriatal DA cell loss characteristic of the disease process, including nigrostriatal lesions with the neurotoxin, 6-hydroxydopamine (6-OHDA), and peripheral injection of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or rotenone. Such models have been used extensively to investigate the motor symptoms of PD since the 1970s. For example, Tadaiesky and colleagues (2008) observed that partial, bilateral 6-OHDA lesions induced symptoms of depression and anxiety using several well established behavioral measures (depression: forced swim test, sucrose consumption; anxiety: elevated plus maze; see also Branchi et al., 2008). Though no studies have investigated the effects of MPTP administration in non-human primates on affect, MPTP-treated mice show profound increases in immobility in the tail-suspension test, a sensitive behavioral measure of depression-like symptoms (Mori et al., 2005; but see Vuckovic et al., 2008).

In addition, genetic mouse models have more recently been developed which address abnormalities associated with familial PD, including mutations in Parkin, PINK1, and DJ1. Though research on the affective symptoms induced within these models has been scarce, a few studies have reported anxiety and depression symptoms. For instance, Zhu and colleagues (2007) reported increased anxiety-like behavior in open field and light-dark box in Parkin null mice, though the effects on anxiety in a mouse model which overexpressed A53T synuclein were contradictory (George et al., 2008). In a novel vesicular monoamine transporter-2 (VMAT-2) deficient mouse model of PD, mice displayed enhanced anxiety and depression-like behaviors, which became more severe with advancing age (Taylor et al., 2009).

As in the human clinical literature, the effect of L-DOPA on affective symptoms is equally unclear in animal models. While chronic L-DOPA treatment in intact rats has been shown to
increase immobility in the forced swim test (Borah & Mohanakumar, 2007), only two studies have attempted to address the effects of L-DOPA treatment on affective symptoms in animal models of PD. Winter and colleagues (2007) observed an increase in learned helplessness behaviors in rats following unilateral 6-OHDA lesions of the substantia nigra pars compacta, which was partially alleviated by acute L-DOPA treatment. In contrast, no benefits of chronic L-DOPA treatment in unilateral, 6-OHDA-lesioned rats were imbued in several measures of anxiety and depression in our laboratory, though mild anxiogenic effects of L-DOPA were detected (Eskow Jaunarajs et al., in press).

The utility of animal models to study affective disorders in PD is evident, since such research allows for precise control over L-DOPA dosage, DA depletion, genetic variability, and countless other variables that are a challenge to human PD research. However, an additional value of animal models is the multiple methods available to assess the behavioral, neurophysiological, and neurochemical effects of both DA cell loss and subsequent L-DOPA therapy. In fact, recent research using 6-OHDA-lesioned rats has hinted that L-DOPA treatment perturbs monoaminergic systems and could induce the development of affective disorders (Eskow Jaunarajs et al., in press; Navailles et al., 2010a, 2010b).

5. Possible monoaminergic mechanisms of anxiety and depression in PD

Traditionally, PD is thought of as a disorder associated with nigrostriatal DA cell loss and as such dopaminergic influences are more widely studied in the expression of affective disorders in PD. However, it is almost certain that dopaminergic depletion only hints at the collective monoaminergic dysfunction that is evident in the Parkinsonian brain. According to Braak staging of PD pathology, NE dysfunction likely occurs prior to significant degradation of DA neurons (Braak et al., 2004). Serotonergic cell loss in the raphe nuclei is also evident prior to nigral DA neuron death (Braak et al., 2004; del Tredici et al., 2002). Furthermore, recent research suggests that the noradrenergic and serotonergic systems may play a more significant role in the manifestation of PD-related anxiety and depression than previously thought.

5.1. Dopamine

Several studies have noted that the onset of affective disorders predates the emergence of Parkinsonian motor symptoms in a subset of PD patients (Nilsson et al., 2001; Schuurman et al., 2002) and in preclinical animal models of PD (Branchi et al., 2008; Mori et al., 2005; Tadaiesky et al., 2008; Taylor et al., 2009). Since motor symptoms typically do not manifest until ~70% of nigral DA neurons have been lost, affective behaviors may be more sensitive to such depletion. Furthermore, DA has been linked to the development and treatment of affective disorders in the general population and in animal models of depression and anxiety (Chen & Skolnick, 2007; Dunlop & Nemeroff, 2007). Thus, anxiety and depression may be linked to the progressive loss of DA neurons that is the cardinal feature of PD pathophysiology. Indeed, Remy and colleagues (2005) found an association between decreased binding to DA transporters in the left ventral striatum and depressive and anxious symptoms (see also Weintraub et al., 2004). In corroboration, nigral neuronal loss was 7 times greater in postmortem brains of PD patients with depression compared to non-depressed PD patients (Frisina et al., 2009), suggesting that depression may be the result of more severe DA-depletion.

If the enhanced prevalence of affective disorders in PD were solely due to DA cell loss, DA replacement therapy with L-DOPA should reliably reduce anxiety and depression. However, de novo patients exposed to L-DOPA have not shown consistent improvement despite substantial reductions in the motor symptoms of PD (Choi et al., 2000; Kim et al., 2009), as described previously. Furthermore, DA-depleted rats expressed enhanced learned
helplessness behaviors that were only partially alleviated by DA replacement therapy with L-DOPA (Winter et al., 2007). The inability of L-DOPA treatment to reliably improve affect may be associated with the supraphysiological release of DA into brain regions related to affect, such as the prefrontal cortex and hippocampus, as observed by Navailles and colleagues (2010a) in unilateral 6-OHDA-lesioned rats. Supraphysiological release of DA is purported as a trigger for psychosis and agitation, which may contribute to anxiety and depression in PD patients. These findings suggest that DA depletion may induce a susceptibility to affective disorders, but does not fully account for the onset of anxiety and depression in PD.

5.2. Norepinephrine

The NE system has been implicated in the expression of affective disorders and evidence for their involvement stems predominantly from the effectiveness of compounds that enhance NE release (Delgado & Moreno, 2000; Ressler & Nemeroff, 2000). In fact, noradrenergic antidepressants, such as nortriptyline have recently proven to be more effective than selective 5-HT reuptake inhibitors in PD patients with depression (SSRIs; Menza et al., 2009), and may suggest a more prominent role for NE. In support, the NE system is certainly affected by the disease process, as evidenced by the profound loss of noradrenergic neurons in the locus coeruleus that occurs prior to DA cell loss within the substantia nigra (Braak et al., 2004; Frisina et al., 2009). Due to NE loss, significant changes in the expression of NE receptors and transporters may prompt the development or exacerbation of anxiety. For example, PD patients exhibit susceptibility to panic attacks induced by yohimbine, an α2-adrenergic antagonist, similar to those in psychiatric patients with panic disorder (Richard et al., 1999). Furthermore, lower DA/NE transporter binding in the locus coeruleus is correlated with increased incidence of anxiety and depression in PD patients (Remy et al., 2005). While plasma NE is actually elevated in de novo PD patients (Ahlskog et al., 1996), lower levels of dopamine β-hydroxylase, the enzyme responsible for hydroxylation of DA to NE, have been observed in the cerebrospinal fluid of L-DOPA-treated PD patients (Nagatsu & Sawada, 2007; O'Connor et al., 1994) and imply that L-DOPA treatment may alter NE levels.

NE levels should intuitively increase upon DA replacement therapy with L-DOPA as NE is catabolized from DA via dopamine β-hydroxylase. However, acute L-DOPA treatment does not appear to bolster NE levels (Chia et al., 1993; Everett & Borcherding, 1970). In fact, Nicholas and colleagues (2008) reported that NE levels in the striatum and olfactory bulb were reduced upon L-DOPA administration in MPTP-treated mice. These findings were recently corroborated in a unilateral, 6-OHDA-lesioned rat model of PD where we reported reduced tissue NE levels in the striatum, hippocampus and prefrontal cortex (Eskow Jaunarajs et al., in press).

A possible mechanism underlying these effects has been suggested through studies which propose that DA is co-released with NE via dopamine β-hydroxylase deficiency (Man in ‘t Veld et al., 1988; Timmers et al., 2004). Following DA cell loss, studies have shown that L-DOPA is converted to DA within noradrenergic neurons and released into forebrain areas (Arai et al., 2008; Nishi et al., 1991). While beneficial to movement and other DA-related functions, L-DOPA-induced DA release from NE terminals may usurp NE release, leading to a paucity of this crucial neurotransmitter at traditionally noradrenergic synapses. In support, Vardi and colleagues (1979) observed that L-DOPA administration to PD patients resulted in significant reductions in dopamine β-hydroxylase activity. However, future studies are necessary to determine the exact mechanism of L-DOPA’s interference with dopamine β-hydroxylase and other aspects of NE function.
5.3. Serotonin

The 5-HT system has been the focus of a large proportion of research on affective disorders and is also affected by the PD process in most patients (Albin et al., 2008; Guttmann et al., 2007; Halliday et al., 1990a,b; Kish et al., 2008) and in some animal models of PD (Nayyar et al., 2009; Ren & Feng, 2007; Vuckovic et al., 2008). However, in a recent neuroanatomical study, Frisina and colleagues (2008) found neuronal loss and gliosis in the substantia nigra pars compacta and locus coeruleus of PD patients with depression but did not observe any pathophysiology in the raphe nuclei, the densest region of 5-HT neurons within the brain. Moreover, acute tryptophan depletion in a small group of human PD patients has not been shown to exacerbate or induce depression or anxiety (Leentjens et al., 2006). In contrast, others have observed increased pathology in the raphe of depressed compared to non-depressed PD patients (Becker et al., 1997; Paulus & Jellinger, 1991).

Tryptophan hydroxylase (TPH) activity and tetrahydrobiopterin, a necessary cofactor for 5-HT catabolism, are also reduced (Nagatsu et al., 1981; Sawada et al., 1985; Yamaguchi et al., 1983) and levels of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT, were found to be lower in the cerebrospinal fluid of depressed PD patients in several studies (Kostic et al., 1987; Mayeux et al., 1984, 1986). Conversely, these effects were not observed in depressed “de novo” patients that had not yet begun DA replacement therapy with L-DOPA, suggesting that treatment or disease progression may somehow lead to a reduction in 5-HT release (Kuhn et al., 1996).

Like NE, L-DOPA treatment has been implicated in 5-HT dysfunction. In intact rats, Borah and Mohanakumar (2007) observed that DA and its metabolites were increased at the expense of reduced 5-HT release in the dorsal raphe nucleus, striatum, and prefrontal cortex after 60 days of L-DOPA administration. This effect appears to hold true in the parkinsonian brain. Maruyama and colleagues (1992) observed a significant reduction in 5-HT metabolism (reduced 5-HIAA/TPH ratio) in PD patients and DA-depleted rats receiving L-DOPA treatment. Other preclinical investigations have maintained that rats chronically treated with L-DOPA show reduced striatal and amygdalar 5-HT and 5-HIAA levels (Carta et al., 2007; Eskow Jaunarajs et al., in press). These results were recently bolstered by studies with in vivo microdialysis by Navailles and colleagues (2010a) as significant dose-dependent reductions in 5-HT release within the hippocampus and prefrontal cortex ipsilateral to the lesion were observed following acute L-DOPA treatments in anaesthetized, hemiparkinsonian rats.

The mechanistic link between L-DOPA administration and 5-HT dysfunction has yet to be discerned, though there are several possibilities. First, L-DOPA may be competing with the serotonin precursor, 5-hydroxytryptophan for conversion via AADC. However, no reports have suggested that this enzyme is rate-limiting. Second, L-DOPA may inhibit tryptophan hydroxylase (TPH; Hashiguti et al., 1993). Since DRN 5-HT neurons lack the protective antioxidant mechanisms of SNpc DA neurons, they may be more vulnerable to interference from byproducts of L-DOPA/DA synthesis and metabolism, such as quinones formed from L-DOPA or DA. In support, Kuhn and Arthur (1998, 1999) found that in vitro exposure of TPH to L-DOPA-quinones results in inactivation of the catalytic core of the TPH enzyme, substantially reducing 5-HT catabolism. We recently demonstrated that chronic L-DOPA for 8 weeks resulted in a marked reduction in TPH expression within the dorsal raphe nucleus in rats lesioned bilaterally with 6-OHDA (Figure 1A), despite no difference in the extent of the DA-lesion measured by TH and dopamine transporter (DAT) versus vehicle-treated rats (Figure 1B). Finally, much like the NE system, 5-HT neurons may also act as surrogates for the DA system following severe DA loss by taking up exogenous L-DOPA, converting it to DA, and releasing it in forebrain areas at the expense of their normal serotonergic function. For example, NE and 5-HT fibers form functional synapses that have been shown to take up exogenously administered L-DOPA and convert and release L-DOPA-derived DA into the...
striatum as a “false neurotransmitter” (Arai et al., 2008; Carta et al., 2007; Eskow et al., 2009; Kannari et al., 2001; Ng et al., 1970). This phenotypic alteration has been suggested to result in reductions in 5-HT following L-DOPA treatment in hemiparkinsonian rats (Carta et al., 2008; Navailles et al., 2010a, 2010b). Such inhibition could be the driving force behind changes in 5-HT neuronal function following chronic L-DOPA treatment, which may spur development of affective symptoms.

6. Conclusion

A number of unconfirmed hypotheses exist for the neural correlates of affective disorders in PD. Depletion of NE and 5-HT levels as the neurons are appropriated by dopaminergic processes could explain the worsening or development of anxiety and depression observed in PD patients undergoing chronic DA replacement therapy (Figure 2), as well as other non-motor symptoms including sleep disturbances, cognitive deficit and autonomic dysfunction. DA release from non-dopaminergic neurons may also be unregulated by appropriate autoreceptor mechanisms and may lead to the expression of other complications of L-DOPA treatment, including L-DOPA-induced dyskinesia (de la Fuente-Fernandez et al., 2004; Jenner, 2008), compulsions (Voon & Fox, 2007), and psychosis (Fenelon et al., 2008). Though it may be difficult to directly test in human patients, several distinct animal models for PD exist that could potentially address these questions. However, these methods have only recently been employed to explore the psychiatric effects of both DA depletion and subsequent L-DOPA treatment and more investigation is essential. In all, discovering the mechanisms behind affective complications in PD may be an exciting new avenue for researchers. Furthermore, additional depiction of these mechanisms in the compromised brain may extend their application to the underlying origin of affective disorders in the general population.

Research Highlights

Parkinson's disease patients have high incidences of affective disorders
L-DOPA treatment does not reliably improve affective symptoms
L-DOPA is taken up by NE and 5-HT neurons and released as a false neurotransmitter
L-DOPA may worsen or induce anxiety and depression by perturbing NE and 5-HT systems

Acknowledgments

We would like to thank Kristin B. Dupre and Dr. Terrence Deak for their helpful discussion.

Supported by NINDS grant NIH NS059600 (CB) and the Center for Development and Behavioral Neuroscience at Binghamton University.

References


Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819–33. [PubMed: 17452372]


Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem 2001;76:1346–53. [PubMed: 11238719]


Figure 1.
Effect of bilateral, intracerebroventricular 6-OHDA lesion and subsequent L-DOPA treatment on A) tryptophan hydroxylase-2 (TPH-2), and B) tyrosine hydroxylase (TH) and C) dopamine transporter (DAT) expression in the dorsal raphe nucleus (DRN) and striatum, respectively. Animals were injected bilaterally with either vehicle (0.1% ascorbic acid in 0.9% NaCl) or 6-OHDA (200 μg in 10 μL) into the lateral ventricles. Three weeks later, rats received either Vehicle (0.1% ascorbic acid in 0.9% NaCl) or L-DOPA methyl ester (12 mg/kg + benserazide, 15 mg/kg, sc) once daily for approximately 75 days resulting in 4 groups: Sham-VEH, Sham-L-DOPA, Lesion-VEH, Lesion-L-DOPA. Rats were killed 1 h after their last treatment and the DRN and striatum were microdissected and flash-frozen for Western blot analysis of TPH-2 and TH, respectively. Bars represent percentage of TPH-2, TH, and DAT expression versus Sham-VEH (100%) + SE (n=4–6/group). Two-way ANOVA revealed a significant main effect of 6-OHDA lesion (TPH-2: F1,14=29.40, p<0.05; TH: F1,14=73.27, r2=0.5, p<0.05; DAT: F1,14=39.90, r2<0.05) and a lesion by treatment interaction (TPH-2: F1,14=4.78, p<0.05). Significant differences between groups were determined via LSD post hoc comparisons (*p<0.05 vs. Sham-VEH, +p<0.05 vs. Sham-LD, #p<0.05 vs. Lesion-VEH).
Figure 2.
Representation of possible effects of PD and subsequent L-DOPA treatment on the forebrain monoaminergic synapses. A) In the normal brain, balance is maintained between NE, 5-HT, and DA release among forebrain post-synaptic neurons that ensures normal affective behaviors. B) Following the loss of SNc neurons, DA loss modifies synaptic neurotransmission and may induce either the onset or a susceptibility to affective disorders. C) While exogenous L-DOPA treatment replaces DA within the synapse, it may supplant non-dopaminergic neurotransmission. For example, 5-HT and NE neurons take up L-DOPA via their respective transporters, convert it to DA via AADC, and release it in forebrain regions following DA depletion (Arai et al., 2008; Kannari et al., 2001). Such mechanisms have preliminarily been shown to usurp NE and/or 5-HT function (Eskow Jaunarajs et al., in press; Navailles et al., 2010a, 2010b). The reduction in 5-HT and NE function may portend the onset or exacerbation of anxiety and depression in PD patients undergoing L-DOPA treatment.
### Table 1

Investigations of effects of L-DOPA treatment on symptoms of anxiety and depression in Parkinson’s disease patients.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Rating Scale</th>
<th>n</th>
<th>Dose of L-DOPA (mg/day)</th>
<th>De novo?</th>
<th>Treatment Duration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>L-DOPA Improves Anxiety and Depression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fung et al., 2009</td>
<td>PDQ-8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>184</td>
<td>300–800</td>
<td>No</td>
<td>3 months</td>
<td>L-DOPA/carbidopa/entacapone improved mood</td>
</tr>
<tr>
<td>Cantello et al., 1986</td>
<td>BDI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>18</td>
<td>780&lt;sup&gt;h&lt;/sup&gt;</td>
<td>No</td>
<td>NA</td>
<td>BDI scores improved during ON phase of treatment</td>
</tr>
<tr>
<td>Witt et al., 2006</td>
<td>BDI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>15</td>
<td>915&lt;sup&gt;h&lt;/sup&gt;</td>
<td>No</td>
<td>Acute</td>
<td>Treatment improved BDI and apathy scores during ON phase</td>
</tr>
<tr>
<td>Funkiewiez et al., 2006</td>
<td>ARCI&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22</td>
<td>1420&lt;sup&gt;h&lt;/sup&gt;</td>
<td>No</td>
<td>NA</td>
<td>Treatment improved anxiety and well-being during ON phase</td>
</tr>
<tr>
<td>Stacy et al., 2010</td>
<td>WOQ-9&lt;sup&gt;d&lt;/sup&gt;</td>
<td>216</td>
<td>NA</td>
<td>No</td>
<td>NA</td>
<td>Treatment improved anxiety and depression during ON phase</td>
</tr>
<tr>
<td><strong>L-DOPA Does Not Affect Anxiety and Depression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim et al., 2009</td>
<td>NMSS&lt;sup&gt;e&lt;/sup&gt;</td>
<td>23</td>
<td>376&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Yes</td>
<td>3 months</td>
<td>Treatment did not improve anxiety or mood</td>
</tr>
<tr>
<td>Marsh &amp; Markham, 1973</td>
<td>MMPI&lt;sup&gt;f&lt;/sup&gt;</td>
<td>27</td>
<td>4440&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Yes</td>
<td>3 and 15 months</td>
<td>Treatment did not change depression scores</td>
</tr>
<tr>
<td><strong>L-DOPA Exacerbates Anxiety and Depression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choi et al., 2000</td>
<td>BDI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>34</td>
<td>560&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Yes</td>
<td>6–28 months</td>
<td>More patients were depressed after onset of treatment</td>
</tr>
<tr>
<td>Negre-Pages et al., 2009</td>
<td>HADS&lt;sup&gt;g&lt;/sup&gt;</td>
<td>422</td>
<td>957&lt;sup&gt;h&lt;/sup&gt;</td>
<td>No</td>
<td>NA</td>
<td>Treatment associated with depression</td>
</tr>
<tr>
<td>Damasio et al., 1970</td>
<td>BDI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>48</td>
<td>2000–5000&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Yes</td>
<td>&gt;3 months</td>
<td>Treatment associated with exacerbation of depression and psychosis</td>
</tr>
</tbody>
</table>

<sup>a</sup>Parkinson’s Disease Questionnaire (8 question version)

<sup>b</sup>Beck Depression Inventory

<sup>c</sup>Addiction Research Center Inventory

<sup>d</sup>Wearing-Off Questionnaire (9 question version)

<sup>e</sup>Non-Motor Symptom Subscale

<sup>f</sup>Minnesota Multiphasic Personality Inventory

<sup>g</sup>Hamilton Anxiety and Depression Scale

<sup>h</sup>not methyl ester form

<sup>i</sup>average dose
Table 2
Investigations of effects of DA depletion and L-DOPA treatment on anxiety and depression symptoms in animal models of Parkinson’s disease.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Species</th>
<th>PD model</th>
<th>L-DOPA dose$^a$</th>
<th>Treatment Length</th>
<th>Behavioral Tests</th>
<th>Effect of Model</th>
<th>Effect of L-DOPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tadaiesky et al., 2008 (see also Branchi et al., 2008)</td>
<td>Rat</td>
<td>Striatal 6-OHDA (bilateral)</td>
<td>--</td>
<td>--</td>
<td>Elevated Plus Maze</td>
<td>Anxiogenic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Forced Swim Test</td>
<td>Depressogenic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sucrose Consumption</td>
<td>Depressogenic</td>
<td>--</td>
</tr>
<tr>
<td>Vuckovic et al., 2008</td>
<td>Mouse</td>
<td>MPTP</td>
<td>--</td>
<td>--</td>
<td>Tail Suspension Test</td>
<td>No effect</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sucrose Preference</td>
<td>No effect</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Light-Dark Box</td>
<td>No effect</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hole-Board Test</td>
<td>No effect</td>
<td>--</td>
</tr>
<tr>
<td>Zhu et al., 2007</td>
<td>Mouse</td>
<td>Parkin null</td>
<td>--</td>
<td>--</td>
<td>Open Field</td>
<td>Anxiogenic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Light-Dark Box</td>
<td>Anxiogenic</td>
<td>--</td>
</tr>
<tr>
<td>George et al., 2008</td>
<td>Mouse</td>
<td>A53T synuclein transgenic</td>
<td>--</td>
<td>--</td>
<td>Elevated Plus Maze</td>
<td>Anxiolytic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Open Field</td>
<td>Anxiogenic</td>
<td>--</td>
</tr>
<tr>
<td>Taylor et al., 2009</td>
<td>Mouse</td>
<td>VMAT-2 deficiency</td>
<td>--</td>
<td>--</td>
<td>Forced Swim Test</td>
<td>Depressogenic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Tail Suspension Test</td>
<td>Depressogenic</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Elevated Plus Maze</td>
<td>Anxiogenic</td>
<td>--</td>
</tr>
<tr>
<td>Mori et al., 2005</td>
<td>Mouse</td>
<td>MPTP</td>
<td>30/100</td>
<td>Acute</td>
<td>Tail Suspension Test</td>
<td>Depressogenic</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Borah &amp; Mohanakumar, 2007</td>
<td>Rat</td>
<td>--</td>
<td>250</td>
<td>60 days</td>
<td>Forced Swim Test</td>
<td>--</td>
<td>Depressogenic</td>
</tr>
<tr>
<td>Winter et al., 2007</td>
<td>Rat</td>
<td>SNpc 6-OHDA (unilateral)</td>
<td>25</td>
<td>3 days</td>
<td>Learned Helplessness</td>
<td>Depressogenic</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Eskow Jaunarajs et al., 2010</td>
<td>Rat</td>
<td>MFB 6-OHDA (unilateral)</td>
<td>12</td>
<td>75 days</td>
<td>Locomotor Chambers</td>
<td>Anxiogenic</td>
<td>Anxiogenic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Forced Swim Test</td>
<td>Depressogenic</td>
<td>No effect</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Social Interaction</td>
<td>Anxiogenic</td>
<td>Anxiogenic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sucrose Consumption</td>
<td>No effect</td>
<td>No effect</td>
</tr>
</tbody>
</table>

$^a$ mg/kg/day